<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK542806" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK542806/" /><meta name="ncbi_pagename" content="Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/06/20" /><meta name="citation_author" content="Rebecca Ganetzky" /><meta name="citation_author" content="Carol Stojinski" /><meta name="citation_pmid" content="31219693" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK542806/" /><meta name="citation_keywords" content="ECHS1D" /><meta name="citation_keywords" content="ECHS1 Deficiency" /><meta name="citation_keywords" content="Mitochondrial Short-Chain Enoyl-CoA Hydratase Deficiency" /><meta name="citation_keywords" content="SCEH Deficiency" /><meta name="citation_keywords" content="ECHS1D" /><meta name="citation_keywords" content="ECHS1 Deficiency" /><meta name="citation_keywords" content="Mitochondrial Short-Chain Enoyl-CoA Hydratase Deficiency" /><meta name="citation_keywords" content="SCEH Deficiency" /><meta name="citation_keywords" content="Enoyl-CoA hydratase, mitochondrial" /><meta name="citation_keywords" content="ECHS1" /><meta name="citation_keywords" content="Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Rebecca Ganetzky" /><meta name="DC.Contributor" content="Carol Stojinski" /><meta name="DC.Date" content="2019/06/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK542806/" /><meta name="description" content="Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) represents a clinical spectrum in which several phenotypes have been described:" /><meta name="og:title" content="Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) represents a clinical spectrum in which several phenotypes have been described:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK542806/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/echs1-def/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK542806/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BD02BE0416001000000000125006E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK542806_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK542806_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mngie/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mws/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK542806_"><span class="title" itemprop="name">Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: ECHS1D, ECHS1 Deficiency, Mitochondrial Short-Chain Enoyl-CoA Hydratase Deficiency, SCEH Deficiency</div><p class="contrib-group"><span itemprop="author">Rebecca Ganetzky</span>, MD and <span itemprop="author">Carol Stojinski</span>, MS, MD.</p><a data-jig="ncbitoggler" href="#__NBK542806_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK542806_ai__"><div class="contrib half_rhythm"><span itemprop="author">Rebecca Ganetzky</span>, MD<div class="affiliation small">Assistant Professor of Pediatrics<br />Division of Human Genetics<br />Children's Hospital of Philadelphia<br />Philadelphia, Pennsylvania<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.pohc.liame@rykztenag" class="oemail">ude.pohc.liame@rykztenag</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Carol Stojinski</span>, MS, MD<div class="affiliation small">Drexel University College of Medicine<br />Philadelphia, Pennsylvania<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.lexerd@284sac" class="oemail">ude.lexerd@284sac</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 20, 2019</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="echs1-def.Summary" itemprop="description"><h2 id="_echs1-def_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) represents a clinical spectrum in which several phenotypes have been described:</p><ul><li class="half_rhythm"><div>The most common <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> presents in the neonatal period with severe encephalopathy and lactic acidosis and later manifests Leigh-like signs and symptoms. Those with presentation in the neonatal period typically have severe hypotonia, encephalopathy, or neonatal seizures within the first few days of life. Signs and symptoms typically progress quickly and the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual ultimately succumbs to central apnea or arrhythmia.</div></li><li class="half_rhythm"><div>A second group of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals present in infancy with developmental regression resulting in severe developmental delay.</div></li><li class="half_rhythm"><div>A third group of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have normal development with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> paroxysmal dystonia that may be exacerbated by illness or exertion.</div></li></ul><p>Across all three groups, T<sub>2</sub> hyperintensity in the basal ganglia is very common, and may affect any part of the basal ganglia.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of ECHS1D is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ECHS1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> or low short-chain enoyl-CoA hydratase (SCEH) activity using cultured skin fibroblasts.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment of severe metabolic acidosis with bicarbonate therapy; hyperammonemia (which may be related to severe acidosis or low ATP from impaired aerobic oxidation) may be addressed by treatment of the metabolic acidosis and/or consideration of hemodialysis. Inadequate nutrition may require feeding therapy; placement of a feeding tube may be considered. Paroxysmal dystonia may respond to benzodiazepines, whereas chronic dystonia may require botulinum toxin injections. Treatment of dystonia with levodopa may also be considered. Standard treatment for seizures, cardiomyopathy, pulmonary hypertension, optic atrophy, sensorineural hearing loss, and developmental delay.</p><p><i>Surveillance:</i> At least annual echocardiogram, dilated eye examination, and audiologic evaluation. Routine monitoring for neurologic symptoms and developmental issues. Assessment of acid/base status and blood lactate level with all illnesses or metabolic stressors.</p><p><i>Agents/circumstances to avoid</i>: Mitochondrial toxins (i.e., valproic acid, prolonged propofol infusions); ketogenic diet.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>ECHS1 deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% change of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible if the <i>ECHS1</i> pathogenic variants in the family are known.</p></div></div><div id="echs1-def.Diagnosis"><h2 id="_echs1-def_Diagnosis_">Diagnosis</h2><p>No consensus clinical diagnostic criteria for ECHS1 deficiency (ECHS1D) have been published.</p><div id="echs1-def.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) <b>should be suspected</b> in individuals with clinical features of Leigh syndrome and/or exercise-induced dystonia who have supportive brain MRI and biochemical findings, including early-onset lactic acidosis.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div><b>Neurologic</b></div><ul><li class="half_rhythm"><div>Developmental delay, often severe [<a class="bk_pop" href="#echs1-def.REF.sakai.2015.232">Sakai et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.huffnagel.2018.83">Huffnagel et al 2018</a>, <a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>]</div></li><li class="half_rhythm"><div>Infantile encephalopathy (may be epileptic), hypotonia, and/or spasticity [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>]</div></li><li class="half_rhythm"><div>Dystonia (exercise induced) and/or choreoathetotic movements [<a class="bk_pop" href="#echs1-def.REF.korenke.2016.ps01">Korenke et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.mahajan.2017.185">Mahajan et al 2017</a>]</div></li></ul></li><li class="half_rhythm"><div><b>Growth.</b> Failure to thrive, which may present prenatally as intrauterine growth restriction and/or oligohydramnios in the most severe cases [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]</div></li><li class="half_rhythm"><div><b>Cardiorespiratory</b></div><ul><li class="half_rhythm"><div>Hypertrophic or dilated cardiomyopathy [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nougu_s.2017.e134">Nougu&#x000e8;s et al 2017</a>]</div></li><li class="half_rhythm"><div>Pulmonary hypertension [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>]</div></li></ul></li><li class="half_rhythm"><div><b>Ophthalmologic</b></div><ul><li class="half_rhythm"><div>Optic atrophy [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>]</div></li><li class="half_rhythm"><div>Nystagmus [<a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>]</div></li><li class="half_rhythm"><div>Glaucoma [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>]</div></li><li class="half_rhythm"><div>Strabismus [<a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>]</div></li><li class="half_rhythm"><div>Corneal clouding [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>]</div></li></ul></li><li class="half_rhythm"><div><b>Other</b></div><ul><li class="half_rhythm"><div>Sensorineural hearing loss [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>]</div></li><li class="half_rhythm"><div>Nonspecific <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features or structural abnormalities (no consistent pattern has emerged) [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>]</div></li></ul></li></ul><p><b>Brain MRI findings</b></p><ul><li class="half_rhythm"><div>T<sub>2</sub> hyperintense signal in the basal ganglia (especially putamen and globus pallidus) [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.korenke.2016.ps01">Korenke et al 2016</a>]</div></li><li class="half_rhythm"><div>Cerebral atrophy [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.huffnagel.2018.83">Huffnagel et al 2018</a>]</div></li><li class="half_rhythm"><div>Agenesis or thinning of the corpus callosum [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>]</div></li><li class="half_rhythm"><div>High lactate with normal lactate to pyruvate ratio peak on MR-spectroscopy [<a class="bk_pop" href="#echs1-def.REF.peters.2014.2903">Peters et al 2014</a>, <a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>]</div></li></ul><p><b>Biochemical features</b></p><ul><li class="half_rhythm"><div>Lactic acidosis. Pyruvate may be mildly elevated, elevated proportionally to the lactate, or normal [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.sakai.2015.232">Sakai et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>].</div></li><li class="half_rhythm"><div>Abnormal urine organic acids, including elevations of:</div><ul><li class="half_rhythm"><div>2-methyl-2,3-dihydoxybutyrate [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]</div></li><li class="half_rhythm"><div>Branched-chain ketoacids [<a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]</div></li><li class="half_rhythm"><div>3-hydroxyisovalerate [<a class="bk_pop" href="#echs1-def.REF.huffnagel.2018.83">Huffnagel et al 2018</a>]</div></li><li class="half_rhythm"><div>3-methylglutaconic acid, ketones, and lactate [<a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]</div></li></ul></li><li class="half_rhythm"><div>Elevations of urine acryloyl-cysteamine, acryloyl-l-cysteamine, N-acetyl-acryloyl-cysteine, methacryl-cysteamine, methacryl-cysteamine, or N-acetyl-methacryl-l-cysteamine [<a class="bk_pop" href="#echs1-def.REF.peters.2014.2903">Peters et al 2014</a>, <a class="bk_pop" href="#echs1-def.REF.peters.2015.168">Peters et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.yamada.2015.691">Yamada et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.huffnagel.2018.83">Huffnagel et al 2018</a>]</div></li><li class="half_rhythm"><div>While plasma acylcarnitine profile is often normal, slight elevations of C4 acylcarnitines may be seen [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>].</div></li><li class="half_rhythm"><div>If performed, muscle or fibroblast electron transport chain function (ETC) is typically normal, although mild decreases in complex I, III, IV, or multiple complexes, with residual activity above 30% of control function, can be seen [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.sakai.2015.232">Sakai et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>].</div></li></ul><p>Note: Muscle biopsy is not required to make a diagnosis of ECHS1D.</p></div><div id="echs1-def.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of ECHS1D <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ECHS1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK542806/table/echs1-def.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figechs1defTmoleculargenetictestingus" rid-ob="figobechs1defTmoleculargenetictestingus">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing or <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of ECHS1D is broad, individuals with the distinctive biochemical findings described in <a href="#echs1-def.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#echs1-def.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders with lactic acidosis, Leigh syndrome, and/or dystonia are more likely to be diagnosed using genomic testing (see <a href="#echs1-def.Option_2">Option 2</a>).</p><div id="echs1-def.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of ECHS1D, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ECHS1</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A</b>
<b>mitochondrial disease, Leigh syndrome, or lactic acidosis</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ECHS1</i> and other genes of interest (see <a href="#echs1-def.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="echs1-def.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by early epileptic encephalopathy, Leigh Syndrome, or lactic acidosis, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic (particularly if only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified), an <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="echs1-def.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in ECHS1 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ECHS1</i></td><td headers="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30/31</td></tr><tr><td headers="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_echs1-def.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/31&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="echs1-def.TF.1.1"><p class="no_margin">See <a href="/books/NBK542806/#echs1-def.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="echs1-def.TF.1.2"><p class="no_margin">See <a href="#echs1-def.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="echs1-def.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="echs1-def.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="echs1-def.TF.1.5"><p class="no_margin">One <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual had a larger <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that included <i>ECHS1</i> and adjacent genes [<a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="echs1-def.Clinical_Characteristics"><h2 id="_echs1-def_Clinical_Characteristics_">Clinical Characteristics</h2><div id="echs1-def.Clinical_Description"><h3>Clinical Description</h3><p>Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) has been reported in 40 individuals representing 31 families [<a class="bk_pop" href="#echs1-def.REF.peters.2014.2903">Peters et al 2014</a>, <a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.sakai.2015.232">Sakai et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.yamada.2015.691">Yamada et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.al_mutairi.2017.629">Al Mutairi et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.balasubramaniam.2017.745">Balasubramaniam et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.mahajan.2017.185">Mahajan et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>]. ECHS1D represents a clinical spectrum in which several phenotypes have been described. The most common <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is presentation in the neonatal period with severe encephalopathy and lactic acidosis and later-onset Leigh-like signs and symptoms. A small number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have normal development, exercise-induced dystonia, and basal ganglia abnormalities on MRI [<a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.mahajan.2017.185">Mahajan et al 2017</a>].</p><p><b>Age of onset</b> is soon after birth in a majority of reported individuals (median age of onset: 1 day; range 1 day - 8 years, n=40); only five reported individuals have presented after the first year of life. In five <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, prenatal signs (intrauterine growth restriction and/or oligohydramnios) were identified; two of those individuals were born prematurely [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>].</p><p>Common clinical manifestations are summarized in <a class="figpopup" href="/books/NBK542806/table/echs1-def.T.common_clinical_manifestatio/?report=objectonly" target="object" rid-figpopup="figechs1defTcommonclinicalmanifestatio" rid-ob="figobechs1defTcommonclinicalmanifestatio">Table 2</a> and discussed below.</p><div id="echs1-def.T.common_clinical_manifestatio" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Common Clinical Manifestations of ECHS1 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.T.common_clinical_manifestatio/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.T.common_clinical_manifestatio_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:top;">Clinical Manifestation</th><th id="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="7" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic&#x000a0;<sup>1</sup></b></td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Signal abnormalities in the basal ganglia</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28/32 (88%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Developmental delay</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27/32 (84%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Hypotonia</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21/30 (70%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Dystonia</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15/29 (52%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Seizures</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12/23 (52%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Encephalopathy</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12/31 (39%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Ataxia/choreoathetosis</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5/25 (20%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Growth</b></td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Failure to thrive</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20/32 (62%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Microcephaly</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7/30 (23%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Intrauterine growth restriction</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5/27 (18%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardiomyopathy</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9/15 (60%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Pulmonary hypertension</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3/14 (21%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ophthalmologic</b></td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nystagmus</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10/31 (32%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Optic atrophy</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8/27 (30%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Corneal clouding</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1/27 (4%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sensorineural hearing loss</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13/27 (48%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Apnea</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7/37 (19%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Liver steatosis &#x00026;/or hepatomegaly</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5/6 (83%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Biochemical/</b><br /><b>Enzymatic</b></td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lactic acidemia</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27/36 (75%)</td></tr><tr><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Low PDC activity (in cultured fibroblasts)</td><td headers="hd_h_echs1-def.T.common_clinical_manifestatio_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5/12 (42%)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="echs1-def.TF.2.1"><p class="no_margin">Neurologic manifestations were seen in all 40 individuals reported [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>].</p></div></dd></dl></div></div></div><p><b>Neurologic.</b> Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported have presented with severe hypotonia, encephalopathy, or neonatal seizures within the first few days of life. In this scenario, signs and symptoms typically progress quickly and the affected individual ultimately succumbs to central apnea or arrhythmia [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]. Affected individuals who survive the neonatal period typically have continued truncal hypotonia but develop limb spasticity. They tend to have severe static developmental delay.</p><p>A second group of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals present in infancy (after the neonatal period up to age 24 months) with developmental regression [<a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.yamada.2015.691">Yamada et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>], typically leading to severe developmental delay.</p><p>There have been two reports of individuals with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> paroxysmal dystonia and otherwise normal development. In one report, two of three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were sibs, one of whom had learning disabilities [<a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>]. The other (unrelated) reported individual had attention deficit with hyperactivity disorder [<a class="bk_pop" href="#echs1-def.REF.mahajan.2017.185">Mahajan et al 2017</a>].</p><p>Dystonia, or less commonly choreoathetosis and/or ataxia, is usually chronically present, but is exacerbated by illness or exertion [<a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>].</p><p>Across all three phenotypes, T<sub>2</sub> hyperintensity in the basal ganglia is very common (88%) and may affect any part of the basal ganglia. This is seen even in those whose clinical presentation is limited to paroxysmal exercise-induced dystonia [<a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.mahajan.2017.185">Mahajan et al 2017</a>].</p><p><b>Growth.</b> Most children with ECHS1 deficiency require enteral feeding tubes due to severe developmental delay and hypotonia. Dysphagia has been reported in three individuals, one of whom suffered aspiration events [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.yamada.2015.691">Yamada et al 2015</a>].</p><p><b>Cardiac.</b> Cardiomyopathy may be dilated or hypertrophic. In two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, cardiac hypertrophy was transient [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>]. Three individuals with pulmonary hypertension have been reported [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>]. Two other individuals have had terminal bradycardiac arrhythmias in the setting of lactic acidosis. It is unclear whether this was due to a predisposition to arrhythmia or secondary to overwhelming metabolic acidosis [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.al_mutairi.2017.629">Al Mutairi et al 2017</a>].</p><p><b>Sensorineural hearing loss.</b> Hearing loss may be found incidentally by audiologic screening. Hearing loss may be mild and is often stable. Two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals required hearing aids for severe hearing loss [<a class="bk_pop" href="#echs1-def.REF.tetreault.2015.981">Tetreault et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>].</p><p><b>Liver dysfunction.</b> Hepatomegaly or hepatosplenomegaly has been seen in multiple infantile cases. Liver steatosis is often present in those who have had postmortem examinations. However, no individuals with clinically significant liver dysfunction have been reported [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>].</p><p><b>Biochemical and enzymatic features</b></p><ul><li class="half_rhythm"><div>Lactate levels may be extremely high, causing metabolic acidosis as the primary clinical finding [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.al_mutairi.2017.629">Al Mutairi et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]. However, in cases with onset after the neonatal period, lactic academia may be intermittent [<a class="bk_pop" href="#echs1-def.REF.huffnagel.2018.83">Huffnagel et al 2018</a>].</div></li><li class="half_rhythm"><div>Two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have had moderate hyperammonemia in the setting of profound neonatal metabolic stress, potentially related to their severe metabolic acidosis and/or low ATP secondary to impaired aerobic oxidation. Levels have been reported ranging from 150 to 800 &#x000b5;mol/L in cases with a concommittent pH &#x0003c; 7.1 [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>].</div></li><li class="half_rhythm"><div>Elevated creatine kinase (CK) levels (hyperCKemia) to about 3,000 IU/L in a critically ill newborn [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>] and transient mild hypoglycemia [<a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>] have also been reported.</div></li><li class="half_rhythm"><div>In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, low pyruvate dehydrogenase complex (PDC) activity in cultured fibroblasts is noted in about 40% of cases [<a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]. Low PDC activity has also been noted in lymphocytes as well as liver and skeletal muscle [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>].</div></li></ul><p><b>Other manifestations.</b> Variable <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> facial features and structural anomalies have each been reported in a few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><ul><li class="half_rhythm"><div>Facial features are variable, but may include a long philtrum, similar to what is seen in individuals with pyruvate dehydrogenase deficiency [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.balasubramaniam.2017.745">Balasubramaniam et al 2017</a>].</div></li><li class="half_rhythm"><div>The only recurrent structural abnormality is thinning or absence of the corpus callosum [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>, <a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>].</div></li><li class="half_rhythm"><div>The following have each been described in one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual:</div><ul><li class="half_rhythm"><div>Hypospadias [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>]</div></li><li class="half_rhythm"><div>Gastroschisis [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>]</div></li><li class="half_rhythm"><div>Cutis laxa [<a class="bk_pop" href="#echs1-def.REF.balasubramaniam.2017.745">Balasubramaniam et al 2017</a>]</div></li><li class="half_rhythm"><div>Hypertrichosis [<a class="bk_pop" href="#echs1-def.REF.fitzsimons.2018.1115">Fitzsimons et al 2018</a>]</div></li><li class="half_rhythm"><div>Abnormal lung septation, multiple splenules, and a preauricular tag [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>]</div></li></ul></li></ul><p><b>Prognosis.</b> The prognosis of neonatal-onset ECHS1 deficiency is poor. Of the 18 reported neonatal cases, 16 (89%) are deceased, mostly within days to weeks of birth from overwhelming lactic acidosis, apnea, hypotension, or bradycardia. Of the 13 later-onset cases, five are deceased (38%), all in early childhood.</p><p>In contrast, those with the paroxysmal dystonia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have been mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with no reported deaths and relatively normal cognitive development. There is likely a broad spectrum between the infantile phenotype and the paroxysmal dystonia phenotype, as individuals with paroxysmal dystonia have been diagnosed after metabolic decompensation [<a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>] or stroke-like episodes [Authors, unpublished observation], but this is not yet clear.</p></div><div id="echs1-def.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with the paroxysmal dystonia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have been <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for the pathogenic <a class="figpopup" href="/books/NBK542806/table/echs1-def.T.notable_echs1_variants_discu/?report=objectonly" target="object" rid-figpopup="figechs1defTnotableechs1variantsdiscu" rid-ob="figobechs1defTnotableechs1variantsdiscu">c.518C&#x0003e;T</a> variant and a second <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#echs1-def.REF.korenke.2016.ps01">Korenke et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al 2016</a>, <a class="bk_pop" href="#echs1-def.REF.mahajan.2017.185">Mahajan et al 2017</a>]. The c.518C&#x0003e;T variant, however, has not been identified in affected individuals with other, more severe clinical phenotypes [<a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>].</p></div><div id="echs1-def.Prevalence"><h3>Prevalence</h3><p>ECHS1 deficiency is rare; the exact prevalence and incidence are unknown.</p><p>To date, 40 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals representing 31 families from different ethnic backgrounds / geographic locations &#x02013; including European, East Asian, French Canadian, and Middle Eastern &#x02013; have been reported [<a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>]. No affected individuals of African heritage have yet been reported.</p><p>Additional data are required to determine if the <a class="figpopup" href="/books/NBK542806/table/echs1-def.T.notable_echs1_variants_discu/?report=objectonly" target="object" rid-figpopup="figechs1defTnotableechs1variantsdiscu" rid-ob="figobechs1defTnotableechs1variantsdiscu">c.538A&#x0003e;G</a> (p.Thr180Ala) variant is a French Canadian <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> [<a class="bk_pop" href="#echs1-def.REF.sharpe.2018.e46">Sharpe &#x00026; McKenzie 2018</a>].</p></div></div><div id="echs1-def.Genetically_Related_Allelic_Di"><h2 id="_echs1-def_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>ECHS1</i>.</p></div><div id="echs1-def.Differential_Diagnosis"><h2 id="_echs1-def_Differential_Diagnosis_">Differential Diagnosis</h2><div id="echs1-def.T.disorders_to_consider_in_the" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of ECHS1 Deficiency (ECHS1D)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.T.disorders_to_consider_in_the/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.T.disorders_to_consider_in_the_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features</th></tr><tr><th headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4" id="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/ECHS1D</th><th headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4" id="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from ECHS1D</th></tr></thead><tbody><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pyruvate dehydrogenase complex (PDC) deficiency<br />(OMIM <a href="https://omim.org/phenotypicSeries/PS312170" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS312170</a>)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/608770" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>DLAT</i></a><br /><a href="https://omim.org/entry/607031" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>LIAS</i></a><br /><a href="https://omim.org/entry/300502" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>PDHA1</i></a><br /><a href="https://omim.org/entry/179060" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>PDHB</i></a><br /><i>PDHX</i><br /><i>PDP1</i></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />XL</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Pyruvate dehydrogenase complex deficiency</div></li><li class="half_rhythm"><div>Lactic acidosis</div></li><li class="half_rhythm"><div>&#x02191; pyruvate</div></li><li class="half_rhythm"><div>Normal lactate to pyruvate ratio</div></li><li class="half_rhythm"><div>Long philtrum</div></li><li class="half_rhythm"><div>Corpus callosum hypoplasia</div></li></ul>
</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>May be a complete phenocopy&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Individuals w/ECHS1D may have abnormal acylcarnitine profile or urine organic acids not typically seen in primary PDC deficiency.</div></li></ul>
</td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-hydroxyisobutyryl-CoA hydrolase deficiency (HIBCHD)<br />(OMIM <a href="https://omim.org/entry/250620" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">250620</a>)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HIBCH</i></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Lactic acidosis</div></li><li class="half_rhythm"><div>Basal gangliar lesions</div></li><li class="half_rhythm"><div>&#x02191; 2-methyl-2,3-dihydroxybutyrate</div></li></ul>
</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Organic acid abnormalities typically more pronounced in HIBCH</td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/fbxl4-mtddepl/"><i>FBXL4</i>-related encephalomyopathic mitochondrial DNA depletion syndrome</a></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FBXL4</i></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Neonatal/primary lactic acidosis</div></li><li class="half_rhythm"><div>Variable cardiomyopathy</div></li></ul>
</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>FBXL4 deficiency typically has more striking hyperammonemia.</div></li><li class="half_rhythm"><div>ATP synthase deficiency typically has more prominent 3-methylglutaconic aciduria.</div></li><li class="half_rhythm"><div>ECHS1D may be suspected (rather than FBXL4 or TMEM70 deficiency) if 2-methyl-2,3-dihydroxybutyrate is present or lactate-to-pyruvate ratio is normal.</div></li></ul>
</td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2<br />(OMIM <a href="https://omim.org/entry/614052" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614052</a>)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TMEM70</i></td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial complex I deficiency due to ACAD9 deficiency<br />(OMIM <a href="https://omim.org/entry/611126" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611126</a>)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ACAD9</i></td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other Leigh syndromes (see <a href="/books/n/gene/leigh-nucl-ov/">Nuclear Gene-Encoded Leigh Syndrome Overview</a> &#x00026; <a href="/books/n/gene/narp/">Mitochondrial DNA-Associated Leigh Syndrome and NARP</a>)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;60 genes</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />mt<br />XL</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>T<sub>2</sub> hyperintensity of the basal ganglia</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Developmental regression</div></li><li class="half_rhythm"><div>Lactic acidosis</div></li></ul>
</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ECHS1D may be clinically indistinguishable from other Leigh syndromes.</td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Paroxysmal exercise-induced dyskinesia &#x00026; epilepsy (see <a href="/books/n/gene/glut1/">Glucose Transporter Type 1 Deficiency Syndrome</a>)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC2A1</i></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR&#x000a0;<sup>2</sup></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Paroxysmal exercise-induced dystonia</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal brain MRI</td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Paroxysmal kinesogenic dyskinesia (see <a href="/books/n/gene/prrt2-parox/"><i>PRRT2</i>-Associated Paroxysmal Movement Disorders</a>)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRRT2</i></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR&#x000a0;<sup>2</sup></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Paroxysmal dystonia (may be exercise induced)</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Normal brain MRI</td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pnknd/">Familial paroxysmal nonkinesigenic dyskinesia</a></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PNKD</i></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pdc/">Pyruvate carboxylase deficiency</a></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PC</i></td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; lactate, pyruvate, &#x00026; ammonia</td><td headers="hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_1_4 hd_h_echs1-def.T.disorders_to_consider_in_the_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>More striking hyperammonemia</div></li><li class="half_rhythm"><div>Ketonuria</div></li><li class="half_rhythm"><div>Normal organic acids</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; mt = mitochondrial; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="echs1-def.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al [2017]</a>, <a class="bk_pop" href="#echs1-def.REF.nougu_s.2017.e134">Nougu&#x000e8;s et al [2017]</a></p></div></dd><dt>2. </dt><dd><div id="echs1-def.TF.3.2"><p class="no_margin">Autosomal recessive inheritance is rare.</p></div></dd></dl></div></div></div></div><div id="echs1-def.Management"><h2 id="_echs1-def_Management_">Management</h2><div id="echs1-def.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D), the evaluations summarized in <a class="figpopup" href="/books/NBK542806/table/echs1-def.T.recommended_evaluations_foll/?report=objectonly" target="object" rid-figpopup="figechs1defTrecommendedevaluationsfoll" rid-ob="figobechs1defTrecommendedevaluationsfoll">Table 4</a> (if they have not already been completed) are recommended.</p><div id="echs1-def.T.recommended_evaluations_foll" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with ECHS1 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.T.recommended_evaluations_foll/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.T.recommended_evaluations_foll_lrgtbl__"><table><thead><tr><th id="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">System/Concern</th><th id="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evaluation</th><th id="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Brain MRI/MRS to evaluate for basal ganglia involvement &#x00026; structural brain anomalies</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Electroencephalogram to evaluate for epileptic encephalopathy</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In those w/neonatal or infantile form</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Growth/</b><br /><b>Gastrointestinal</b></td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Nutritional evaluation</div></li><li class="half_rhythm"><div>Swallowing assessment</div></li><li class="half_rhythm"><div>Liver ultrasound to evaluate for hepatosplenomegaly</div></li></ul>
</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nutritional &#x00026; swallowing evaluations should be performed in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, but liver ultrasound is only necessary in neonates.</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram to evaluate for cardiomyopathy in those w/neonatal form</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Measurement of pulmonary artery pressure is important to evaluate for pulmonary hypertension.</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ophthalmologic</b></td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dilated eye exam to evaluate for optic atrophy &#x00026; other findings</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Audiologic</b></td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Audiologic evaluation to evaluate for sensorineural hearing loss</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Biochemical</b></td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lactate &#x00026; blood gas to evaluate acid/base status</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Blood glucose level</div></li><li class="half_rhythm"><div>Urine organic acids</div></li></ul>
</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For those presenting w/neonatal or infantile form</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Blood ammonia level</div></li><li class="half_rhythm"><div>Creatine kinase level</div></li></ul>
</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For those who present in neonatal period</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental evaluation</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Physical examination &#x00026; consideration of imaging for possible structural anomalies</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For those presenting w/neonatal or infantile form</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_echs1-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div></div></div><div id="echs1-def.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management is best provided by a multidisciplinary team including specialists in clinical genetics / metabolism, neurology, nutrition, and developmental pediatrics. Other specialists, such as a cardiologist and an ophthalmologist, may be involved based on the associated complications. In those presenting in the neonatal period, involvement of a palliative care team is also essential to determine goals of care given the poor prognosis for this group. This should be especially considered for neonates with major structural abnormalities in whom surgical management is being considered.</p><p>No definite treatment is available to date; treatment is mainly supportive (see <a class="figpopup" href="/books/NBK542806/table/echs1-def.T.treatment_of_manifestations/?report=objectonly" target="object" rid-figpopup="figechs1defTtreatmentofmanifestations" rid-ob="figobechs1defTtreatmentofmanifestations">Table 5</a>).</p><div id="echs1-def.T.treatment_of_manifestations" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with ECHS1 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.T.treatment_of_manifestations/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.T.treatment_of_manifestations_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/Concern</th><th id="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dystonia (paroxysmal)</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benzodiazepines</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Levodopa has been tried w/out success in 1 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual;&#x000a0;<sup>1</sup> nonetheless, trial of this low-risk, noninvasive therapy is probably reasonable.</td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dystonia (chronic)</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Botulinum toxin injections</td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard antiepileptic therapy</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Inadequate nutrition</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nasogastric tube or gastrostomy tube; feeding therapy w/speech therapist</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiomyopathy or</b><br /><b>pulmonary hypertension</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment per cardiologist</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Optic atrophy</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low-vision support for educational settings</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N-acetylcysteine &#x00026; vitamin C use may be considered, but evidence for benefit is limited.</td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Sensorineural hearing loss</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing aids</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="/books/n/gene/deafness-overview/">Hereditary Hearing Loss and Deafness Overview</a></td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Acidosis</b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bicarbonate therapy for correction</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sodium citrate &#x00026; acetate are unlikely to provide sufficient buffering capacity in these children w/secondary impairment of the tricarboxylic acid cycle.</td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hyperammonemia&#x000a0;<sup>2</sup></b></td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Correction of metabolic acidosis</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High-concentration dextrose would result in increased lacticemia &#x00026; should be used with caution, if at all.</td></tr><tr><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consideration of hemodialysis</td><td headers="hd_h_echs1-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">It is unknown if nitrogen scavengers would be of benefit.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="echs1-def.TF.5.1"><p class="no_margin"><a class="bk_pop" href="#echs1-def.REF.olgiati.2016.1041">Olgiati et al [2016]</a></p></div></dd><dt>2. </dt><dd><div id="echs1-def.TF.5.2"><p class="no_margin">The origin of the hyperammonemia is unclear. It may be secondary to metabolic acidosis, as it has only been observed in children with profound metabolic acidosis or due to low ATP secondary to impaired aerobic oxidation. Correction of acidosis is a reasonable first strategy.</p></div></dd></dl></div></div></div><p><b>Other treatment considerations</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Anecdotal reports of treatment with N-aceylcysteine to detoxify the reactive metabolites of methacrylyl-CoA and acroyacryl-CoA are mixed.</div></li><li class="half_rhythm"><div class="half_rhythm">Valine restriction would be a rational biochemical approach; it has never been attempted.</div></li><li class="half_rhythm"><div class="half_rhythm">Administration of cofactors and antioxidants, used in mitochondrial disorders with (generally) limited evidence of benefit, may be considered [<a class="bk_pop" href="#echs1-def.REF.parikh.2009.414">Parikh et al 2009</a>].</div><div class="half_rhythm">In one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with paroxysmal exercise-induced dystonia, this "cocktail" produced a subjective improvement [<a class="bk_pop" href="#echs1-def.REF.mahajan.2017.185">Mahajan et al 2017</a>].</div></li></ul><div id="echs1-def.Developmental_Delay__Intellect"><h4>Developmental Delay / Intellectual Disability Management Issues</h4><p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed.</p><p><b>Ages 5-21 years</b></p><ul><li class="half_rhythm"><div>In the US, an IEP based on the individual's level of function should be developed by the local public school district. Affected children are permitted to remain in the public school district until age 21.</div></li><li class="half_rhythm"><div>Discussion about transition plans including financial and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood.</div></li></ul><p><b>All ages.</b> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life.</p><p>Consideration of private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs is recommended. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p><p>In the US:</p><ul><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div></div><div id="echs1-def.Surveillance"><h3>Surveillance</h3><div id="echs1-def.T.recommended_surveillance_for" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with ECHS1 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.T.recommended_surveillance_for/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.T.recommended_surveillance_for_lrgtbl__"><table><thead><tr><th id="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evaluation</th><th id="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recommended Interval</th><th id="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comprehensive neurologic examination &#x00026; developmental assessment</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Depending on symptoms</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Repeat MRI &#x00026; EEG warranted only if symptoms concerning for new developments arise</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard anthropometric monitoring</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">W/routine pediatric follow up</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram to monitor for cardiomyopathy</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children w/cardiomyopathy noted on echocardiogram may need to be followed more closely.</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dilated eye exam to monitor for optic atrophy &#x00026; other ophthalmologic findings</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At ages 6 mos &#x00026; 12 mos, then annually</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children w/ophthalmologic anomalies detected may need to be followed more closely.</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Audiologic evaluation for sensorineural hearing loss</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children w/abnormal hearing screens may need to be followed more closely.</td></tr><tr><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sodium bicarbonate &#x00026; lactate levels to monitor for acidosis</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">W/all illnesses or metabolic stressors</td><td headers="hd_h_echs1-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children on chronic bicarbonate therapy also require routine monitoring of levels.</td></tr></tbody></table></div></div></div><div id="echs1-def.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Mitochondrial toxins, such as valproic acid and prolonged propofol infusions, should be avoided [<a class="bk_pop" href="#echs1-def.REF.parikh.2009.414">Parikh et al 2009</a>].</p><p>The ketogenic diet may be poorly tolerated because of partially impaired fatty acid oxidation [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>]; one preliminary report suggests rapid disease progression following initiation of the ketogenic diet [<a class="bk_pop" href="#echs1-def.REF.nougu_s.2017.e134">Nougu&#x000e8;s et al 2017</a>] and in two other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, subjects perished within days of starting a ketogenic diet [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]. Therefore, ketogenic diet may not be effective to control lactic acidosis and may be harmful or even lethal &#x02013; and thus should be avoided.</p></div><div id="echs1-def.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic younger sibs of an individual <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by the paroxysmal exercise-induced dystonia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>ECHS1</i> pathogenic variants in the family in order to identify as early as possible those who would benefit from early initiation of exercise-guidance and dystonia-targeted therapies.</p><p>In an at-risk newborn, it is crucial to ensure metabolic stability by evaluating a lactic acid level and a blood gas. Urine organic acids and acylcarnitine profile may also be used as biochemical screening testing while waiting for <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> results; they can have high specificity, but <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> may be low.</p><p>See <a href="#echs1-def.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="echs1-def.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="echs1-def.Genetic_Counseling"><h2 id="_echs1-def_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="echs1-def.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>In most instances, the parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are heterozygotes (i.e., carriers of one <i>ECHS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>In rare cases, a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has one <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and one pathogenic variant inherited from a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> parent [<a class="bk_pop" href="#echs1-def.REF.aretini.2018.99">Aretini et al 2018</a>, <a class="bk_pop" href="#echs1-def.REF.carlston.2019.103">Carlston et al 2019</a>]; in these families, presumably only one parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ECHS1</i> pathogenic variant.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>If both parents are carriers, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>If only one parent is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (i.e., the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for an inherited <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant), each sib of the proband has a 50% chance of being an asymptomatic carrier and a 50% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Sibs who inherit two pathogenic variants will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Sibs who inherit one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (heterozygotes) are expected to be asymptomatic. A sib who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an inherited pathogenic variant could be affected if s/he also has another <i>de novo ECHS1</i> pathogenic variant on the other <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (i.e., <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>To date, individuals with the neonatal and infantile forms of ECHS1D are not known to reproduce.</div></li><li class="half_rhythm"><div>Each child of an individual with the paroxysmal dystonia form of ECHS1D has a 50% chance of inheriting the <i>ECHS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul><p><b>Other family members.</b> In general, each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>ECHS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="echs1-def.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>ECHS1</i> pathogenic variants in the family.</p></div><div id="echs1-def.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#echs1-def.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="echs1-def.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ECHS1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="echs1-def.Resources"><h2 id="_echs1-def_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association for Neuro-Metabolic Disorders (ANMD)</b></div><div>5223 Brookfield Lane</div><div>Sylvania OH 43560-1809</div><div><b>Phone:</b> 419-885-1809; 419-885-1497</div><div><b>Email:</b> volk4olks@aol.com</div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>United Mitochondrial Disease Foundation (UMDF)</b></div><div>8085 Saltsburg Road</div><div>Suite 201</div><div>Pittsburg PA 15239</div><div><b>Phone:</b> 888-317-8633 (toll-free); 412-793-8077</div><div><b>Fax:</b> 412-793-6477</div><div><b>Email:</b> info@umdf.org</div><div><a href="http://www.umdf.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.umdf.org</a></div></li><li class="half_rhythm"><div><b>RDCRN Patient Contact Registry: North American Mitochondrial Disease Consortium</b></div><div><a href="https://www.rarediseasesnetwork.org/cms/namdc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Contact Registry</a></div></li></ul></div><div id="echs1-def.Molecular_Genetics"><h2 id="_echs1-def_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="echs1-def.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_echs1-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_echs1-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_echs1-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_echs1-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_echs1-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_echs1-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1892" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ECHS1</i></a></td><td headers="hd_b_echs1-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1892" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q26<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_echs1-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P30084" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Enoyl-CoA hydratase, mitochondrial</a></td><td headers="hd_b_echs1-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ECHS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ECHS1</a></td><td headers="hd_b_echs1-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ECHS1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ECHS1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="echs1-def.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="echs1-def.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency (<a href="/omim/602292,616277" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602292" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602292</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ENOYL-CoA HYDRATASE, SHORT-CHAIN, 1, MITOCHONDRIAL; ECHS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/616277" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">616277</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOCHONDRIAL SHORT-CHAIN ENOYL-CoA HYDRATASE 1 DEFICIENCY; ECHS1D</td></tr></tbody></table></div></div><div id="echs1-def.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The mitochondrial short-chain enoyl-CoA hydratase (SCEH) has a primary function in the beta-oxidation of short-chain fats. However, the same enzyme also is involved in branched-chain amino acid metabolism, particularly valine metabolism [<a class="bk_pop" href="#echs1-def.REF.peters.2014.2903">Peters et al 2014</a>, <a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>]. The enoyl-CoA metabolites of valine catabolism that are the substrates of SCEH, methylacrylyl-CoA, and acryloyl-CoA are highly reactive intermediates [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>]. The most likely cause of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> observed in this disorder is high concentrations of these toxic enoyl-CoA intermediates, which impair the function of pyruvate dehydrogenase complex (PDC) and the mitochondrial respiratory chain; however, the full mechanism(s) of this impairment are not yet fully elucidated [<a class="bk_pop" href="#echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse et al 2015</a>, <a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>]. Regardless of the exact mechanism, secondary deficiency of PDC is observed in about half of reported <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. It is believed that PDC deficiency is an important contributor to the lactic acidosis [<a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>].</p><p><b>Gene structure.</b>
<i>ECHS1</i> has eight exons.</p><p><b>Pathogenic variants.</b> The majority of reported variants have been <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>. A variety of other <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants have also been reported, including a <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#echs1-def.REF.peters.2014.2903">Peters et al 2014</a>], abrogation of the start codon [<a class="bk_pop" href="#echs1-def.REF.sakai.2015.232">Sakai et al 2015</a>], impairment of the mitochondrial targeting sequence [<a class="bk_pop" href="#echs1-def.REF.ganetzky.2016.33">Ganetzky et al 2016</a>], amino acid <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>], and a frameshift pathogenic variant [<a class="bk_pop" href="#echs1-def.REF.haack.2015.492">Haack et al 2015</a>]. With the exception of the recurrent c.518C&#x0003e;T pathogenic variant, all pathogenic variants reported to date have been <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> [<a class="bk_pop" href="#echs1-def.REF.nair.2016.1189">Nair et al 2016</a>].</p><div id="echs1-def.T.notable_echs1_variants_discu" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Notable <i>ECHS1</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK542806/table/echs1-def.T.notable_echs1_variants_discu/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__echs1-def.T.notable_echs1_variants_discu_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.518C&#x0003e;T</td><td headers="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala173Val</td><td headers="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_004092.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004092<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_004083.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004083<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.538A&#x0003e;G</td><td headers="hd_h_echs1-def.T.notable_echs1_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr180Ala</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> SCEH has 290 amino acids. The first 27 amino acids are the mitochondrial targeting sequence.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ECHS1</i> pathogenic variants have loss of SCEH protein function [<a class="bk_pop" href="#echs1-def.REF.bedoyan.2017.342">Bedoyan et al 2017</a>].</p></div></div><div id="echs1-def.References"><h2 id="_echs1-def_References_">References</h2><div id="echs1-def.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.al_mutairi.2017.629">Al Mutairi F, Shamseldin HE, Alfadhel M, Rodenburg RJ, Alkuraya FS. A lethal neonatal phenotype of mitochondrial short-chain enoyl-CoA hydratase-1 deficiency. <span><span class="ref-journal">Clin Genet. </span>2017;<span class="ref-vol">91</span>:629–33.</span> [<a href="/pubmed/27905109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27905109</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.aretini.2018.99">Aretini P, Mazzanti CM, La Ferla M, Franceschi S, Lessi F, De Gregorio V, Nesti C, Valetto A, Bertini V, Toschi B, Battini R, Caligo MA. Next generation sequencing technologies for a successful diagnosis in a cold case of Leigh syndrome. <span><span class="ref-journal">BMC Neurol. </span>2018;<span class="ref-vol">18</span>:99.</span> [<a href="/pmc/articles/PMC6054728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6054728</span></a>] [<a href="/pubmed/30029642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30029642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.balasubramaniam.2017.745">Balasubramaniam S, Riley LG, Bratkovic D, Ketteridge D, Manton N, Cowley MJ, Gayevskiy V, Roscioli T, Mohamed M, Gardeitchik T, Morava E, Christodoulou J. Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>2017;<span class="ref-vol">40</span>:745–7.</span> [<a href="/pubmed/28409271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28409271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.bedoyan.2017.342">Bedoyan JK, Yang SP, Ferdinandusse S, Jack RM, Miron A, Grahame G, DeBrosse SD, Hoppel CL, Kerr DS, Wanders RJA. Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2017;<span class="ref-vol">120</span>:342–9.</span> [<a href="/pmc/articles/PMC5382105/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5382105</span></a>] [<a href="/pubmed/28202214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28202214</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.carlston.2019.103">Carlston CM, Ferdinandusse S, Hobert JA, Mao R, Longo N. Extrapolation of variant phase in mitochondrial short-chain enoyl-CoA hydratase (ECHS1) deficiency. <span><span class="ref-journal">JIMD Rep. </span>2019;<span class="ref-vol">43</span>:103–9.</span> [<a href="/pmc/articles/PMC6323015/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6323015</span></a>] [<a href="/pubmed/29923089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29923089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.ferdinandusse.2015.79">Ferdinandusse S, Friederich MW, Burlina A, Ruiter JP, Coughlin CR 2nd, Dishop MK, Gallagher RC, Bedoyan JK, Vaz FM, Waterham HR, Gowan K, Chatfield K, Bloom K, Bennett MJ, Elpeleg O, Van Hove JL, Wanders RJ. Clinical and biochemical characterization of four patients with mutations in ECHS1. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2015;<span class="ref-vol">10</span>:79.</span> [<a href="/pmc/articles/PMC4474341/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4474341</span></a>] [<a href="/pubmed/26081110" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26081110</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.fitzsimons.2018.1115">Fitzsimons PE, Alston CL, Bonnen PE, Hughes J, Crushell E, Geraghty MT, Tetreault M, O'Reilly P, Twomey E, Sheikh Y, Walsh R, Waterham HR, Ferdinandusse S, Wanders RJA, Taylor RW, Pitt JJ, Mayne PD. Clinical, biochemical, and genetic features of four patients with short-chain enoyl-CoA hydratase (ECHS1) deficiency. <span><span class="ref-journal">Am J Med Genet A. </span>2018;<span class="ref-vol">176</span>:1115–27.</span> [<a href="/pmc/articles/PMC5947294/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5947294</span></a>] [<a href="/pubmed/29575569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29575569</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.ganetzky.2016.33">Ganetzky RD, Bloom K, Ahrens-Nicklas R, Edmondson A, Deardorff MA, Bennett MJ, Ficicioglu C. ECHS1 deficiency as a cause of severe neonatal lactic acidosis. <span><span class="ref-journal">JIMD Rep. </span>2016;<span class="ref-vol">30</span>:33–7.</span> [<a href="/pmc/articles/PMC5110442/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5110442</span></a>] [<a href="/pubmed/26920905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26920905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.haack.2015.492">Haack TB, Jackson CB, Murayama K, Kremer LS, Schaller A, Kotzaeridou U, de Vries MC, Schottmann G, Santra S, B&#x000fc;chner B, et al.  Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement. <span><span class="ref-journal">Ann Clin Transl Neurol. </span>2015;<span class="ref-vol">2</span>:492–509.</span> [<a href="/pmc/articles/PMC4435704/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4435704</span></a>] [<a href="/pubmed/26000322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26000322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.huffnagel.2018.83">Huffnagel IC, Redeker EJW, Reneman L, Vaz FM, Ferdinandusse S, Poll-The BT. Mitochondrial encephalopathy and transient 3-methylglutaconic aciduria in ECHS1 deficiency: long-term follow-up. <span><span class="ref-journal">JIMD Rep. </span>2018;<span class="ref-vol">39</span>:83–7.</span> [<a href="/pmc/articles/PMC5953898/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5953898</span></a>] [<a href="/pubmed/28755360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28755360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.korenke.2016.ps01">Korenke G, Nuoffer J-M, Alhaddad B, Mayr H, Prokisch H, Haack TB. Paroxysmal dyskinesia in ECHS1 defect with globus pallidus lesions. <span><span class="ref-journal">Neuropediatrics. </span>2016;<span class="ref-vol">47</span>:PS01–10.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.mahajan.2017.185">Mahajan A, Constantinou J, Sidiropoulos C. ECHS1 deficiency-associated paroxysmal exercise-induced dyskinesias: case presentation and initial benefit of intervention. <span><span class="ref-journal">J Neurol. </span>2017;<span class="ref-vol">264</span>:185–7.</span> [<a href="/pubmed/28039521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28039521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.nair.2016.1189">Nair P, Hamzeh AR, Mohamed M, Malik EM, Al-Ali MT, Bastaki F. Novel ECHS1 mutation in an Emirati neonate with severe metabolic acidosis. <span><span class="ref-journal">Metab Brain Dis. </span>2016;<span class="ref-vol">31</span>:1189–92.</span> [<a href="/pubmed/27221955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27221955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.nougu_s.2017.e134">Nougu&#x000e8;s MC, Gu&#x000eb;t A, Fazzio M, Danekova N, Valence S, Billette de Villemeur T, Garel C, Rodriguez D, Boutron A. Poor tolerance of ketogenic diet for suspicion of PDH deficiency: what about another diagnosis? <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2017;<span class="ref-vol">21</span>:e134.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.olgiati.2016.1041">Olgiati S, Skorvanek M, Quadri M, Minneboo M, Graafland J, Breedveld GJ, Bonte R, Ozgur Z, van den Hout MC, Schoonderwoerd K, et al.  Paroxysmal exercise-induced dystonia within the phenotypic spectrum of ECHS1 deficiency. <span><span class="ref-journal">Mov Disord. </span>2016;<span class="ref-vol">31</span>:1041–8.</span> [<a href="/pubmed/27090768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27090768</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.parikh.2009.414">Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, et al.  A modern approach to the treatment of mitochondrial disease. <span><span class="ref-journal">Curr Treat Options Neurol. </span>2009;<span class="ref-vol">11</span>:414–30.</span> [<a href="/pmc/articles/PMC3561461/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3561461</span></a>] [<a href="/pubmed/19891905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19891905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.peters.2014.2903">Peters H, Buck N, Wanders R, Ruiter J, Waterham H, Koster J, Yaplito-Lee J, Ferdinandusse S, Pitt J. ECHS1 mutations in Leigh disease: a new inborn error of metabolism affecting valine metabolism. <span><span class="ref-journal">Brain. </span>2014;<span class="ref-vol">137</span>:2903–8.</span> [<a href="/pubmed/25125611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25125611</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.peters.2015.168">Peters H, Ferdinandusse S, Ruiter JP, Wanders RJ, Boneh A, Pitt J. Metabolite studies in HIBCH and ECHS1 defects: implications for screening. <span><span class="ref-journal">Mol Genet Metab. </span>2015;<span class="ref-vol">115</span>:168–73.</span> [<a href="/pubmed/26163321" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26163321</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.sakai.2015.232">Sakai C, Yamaguchi S, Sasaki M, Miyamoto Y, Matsushima Y, Goto Y. ECHS1 mutations cause combined respiratory chain deficiency resulting in Leigh syndrome. <span><span class="ref-journal">Hum Mutat. </span>2015;<span class="ref-vol">36</span>:232–9.</span> [<a href="/pubmed/25393721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25393721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.sharpe.2018.e46">Sharpe AJ, McKenzie M. Mitochondrial fatty acid oxidation disorders associated with short-chain enoyl-CoA hydratase (ECHS1) deficiency. <span><span class="ref-journal">Cells. </span>2018;<span class="ref-vol">7</span>:E46.</span> pii. [<a href="/pmc/articles/PMC6025059/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6025059</span></a>] [<a href="/pubmed/29882869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29882869</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.tetreault.2015.981">Tetreault M, Fahiminiya S, Antonicka H, Mitchell GA, Geraghty MT, Lines M, Boycott KM, Shoubridge EA, Mitchell JJ, Michaud JL, Majewski J, et al.  Whole-exome sequencing identifies novel ECHS1 mutations in Leigh syndrome. <span><span class="ref-journal">Hum Genet. </span>2015;<span class="ref-vol">134</span>:981–91.</span> [<a href="/pubmed/26099313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26099313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="echs1-def.REF.yamada.2015.691">Yamada K, Aiba K, Kitaura Y, Kondo Y, Nomura N, Nakamura Y, Fukushi D, Murayama K, Shimomura Y, Pitt J, Yamaguchi S, Yokochi K, Wakamatsu N. Clinical, biochemical and metabolic characterisation of a mild form of human short-chain enoyl-CoA hydratase deficiency: significance of increased N-acetyl-S-(2-carboxypropyl)cysteine excretion. <span><span class="ref-journal">J Med Genet. </span>2015;<span class="ref-vol">52</span>:691–8.</span> [<a href="/pubmed/26251176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26251176</span></a>]</div></li></ul></div></div><div id="echs1-def.Chapter_Notes"><h2 id="_echs1-def_Chapter_Notes_">Chapter Notes</h2><div id="echs1-def.Author_Notes"><h3>Author Notes</h3><p>Rebecca Ganetzky is an attending physician in the <a href="http://www.chop.edu/centers-programs/mitochondrial-disease-clinical-center" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mitochondrial Medicine Frontier Program at the Children's Hospital of Philadelphia</a>. Her research is on mitochondrial ATP synthase deficiency. She has a special clinical interest in primary lactic acidosis.</p></div><div id="echs1-def.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>20 June 2019 (ma) Review posted live</div></li><li class="half_rhythm"><div>9 April 2018 (rg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK542806</span><span class="label">PMID: <a href="/pubmed/31219693" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31219693</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mngie/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mws/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK542806&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK542806/?report=reader">PubReader</a></li><li><a href="/books/NBK542806/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK542806" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK542806" style="display:none" title="Cite this Page"><div class="bk_tt">Ganetzky R, Stojinski C. Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency. 2019 Jun 20. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK542806/pdf/Bookshelf_NBK542806.pdf">PDF version of this page</a> (494K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#echs1-def.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#echs1-def.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#echs1-def.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#echs1-def.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#echs1-def.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#echs1-def.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#echs1-def.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#echs1-def.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#echs1-def.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#echs1-def.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#echs1-def.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1892[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ECHS1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4788608" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4788608" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4788608" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4788608" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22593918" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shchelochkov OA, Carrillo N, Venditti C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29575569" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical, biochemical, and genetic features of four patients with short-chain enoyl-CoA hydratase (ECHS1) deficiency.</a><span class="source">[Am J Med Genet A. 2018]</span><div class="brieflinkpop offscreen_noflow">Clinical, biochemical, and genetic features of four patients with short-chain enoyl-CoA hydratase (ECHS1) deficiency.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fitzsimons PE, Alston CL, Bonnen PE, Hughes J, Crushell E, Geraghty MT, Tetreault M, O'Reilly P, Twomey E, Sheikh Y, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2018 May; 176(5):1115-1127. Epub 2018 Mar 25.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26081110" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical and biochemical characterization of four patients with mutations in ECHS1.</a><span class="source">[Orphanet J Rare Dis. 2015]</span><div class="brieflinkpop offscreen_noflow">Clinical and biochemical characterization of four patients with mutations in ECHS1.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ferdinandusse S, Friederich MW, Burlina A, Ruiter JP, Coughlin CR 2nd, Dishop MK, Gallagher RC, Bedoyan JK, Vaz FM, Waterham HR, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2015 Jun 18; 10:79. Epub 2015 Jun 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28202214" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency.</a><span class="source">[Mol Genet Metab. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bedoyan JK, Yang SP, Ferdinandusse S, Jack RM, Miron A, Grahame G, DeBrosse SD, Hoppel CL, Kerr DS, Wanders RJA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Genet Metab. 2017 Apr; 120(4):342-349. Epub 2017 Feb 2.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301409" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Isolated Methylmalonic Acidemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Isolated Methylmalonic Acidemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Manoli I, Sloan JL, Venditti CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31219693" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31219693" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0418a1dd21425a2543df1f">Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:19:13-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BD02BE0416001000000000125006E&amp;ncbi_session=CE8BD02BE0418A11_0293SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK542806%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK542806&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK542806/&amp;ncbi_pagename=Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BD02BE0418A11_0293SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>